Global Thrombocytopenia (Immune & Chemotherapy-induced) Market: Insights, Trends and Forecast (2019-2023)
- Koncept Analytics
- September 2019
- 95 pages
The global immune thrombocytopenia (ITP) market is expected to reach 2.27 billion in 2023, growing at a CAGR of 5.82%, for the duration spanning 2019-2023. The factors such as, rising healthcare expenditures, growing female population, rising prevalence of arthritis, increasing incidences of hepatitis C and new cases of diagnosed cancer would drive the growth of the market. However, market growth would be challenged by the lethargic drug approval process, side effects associated with available thrombocytopenia drugs and the availability of alternative treatment options. A few notable trends include, novel drug development for thrombocytopenia, increasing number of awareness programs against thrombocytopenia, and increasing preferences for biosimilars.
The global thrombocytopenia market would witness considerable growth in coming years, due to the rising prevalence of thrombocytopenia and associated risk factors. The most common type of thrombocytopenia is ITP, which is highly prevalent in patients with rheumatoid arthritis. Whereas, CIT (Chemotherapy-Induced Thrombocytopenia) occurs in patients with cancer, due to the involvement of chemotherapy and radiation treatment. Thrombocytopenia in patients with CLD is growing rapidly with an increase in incidences of HCV infections among them.
The fastest growing regional market is the U.S., owing to the high prevalence of thrombocytopenia in patients with cancer as well as chronic liver diseases. Moreover, rising awareness about the symptoms and causes of thrombocytopenia among people, through various campaigns and the FDA approvals of various novel drugs for the treatment of thrombocytopenia would drive considerable growth in the global thrombocytopenia market.
Scope of the report:
- The report provides a comprehensive analysis of the global thrombocytopenia (Immune and Chemotherapy-induced) market.
- The major regional market (the U.S.) has been analyzed.
- The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
- The competitive landscape of the market, along with the company profiles of leading players (Novartis AG, Merck and Co., CSL Limited, Amgen Pharmaceuticals, Horizon Therapeutics and Rigel Pharmaceuticals) are also presented in detail.
Key Target Audience:
- Thrombocytes Drugs Manufacturers
- Chemical Suppliers
- End Users (Hospital, Medical Centers, Clinical Institutes)
- Healthcare Consulting Firms
- Investment Banks
- Government Bodies & Regulating Authorities
Have query on this report?Make an Enquiry
Table of Content
1.2 Causes of Thrombocytopenia
1.3 Symptoms of Thrombocytopenia
1.4 Diagnosis of Thrombocytopenia
1.5 Treatment of Thrombocytopenia
1.6 Pathophysiology of Thrombocytopenia
2. Global Thrombocytopenia Market
2.1 Global ITP Market
2.1.1 Global ITP Market Forecast by Value
2.1.2 Global ITP Total Patient Volume Forecast
2.1.3 Global ITP Total Patient Volume Forecast by Region
2.1.4 Global ITP Treated Patient Volume Forecast
2.1.5 Global ITP Treated Patient Volume Forecast by Region
2.2 Global CIT Market
2.2.1 Global CIT Total Patient Volume Forecast
2.2.2 Global CIT Total Patient Volume Forecast by Region
2.2.3 Global CIT Treated Patient Volume Forecast
2.2.4 Global CIT Treated Patient Volume Forecast by Region
3. Regional Thrombocytopenia Market
3.1 The U.S.
3.1.1 The U.S. ITP Total Patient Volume Forecast
3.1.2 The U.S. ITP Treated Patient Volume Forecast
3.1.3 The U.S. Doptelet ITP Treated Patient Volume Forecast
3.1.4 The U.S. CIT Total Patient Volume Forecast
3.1.5 The U.S. CIT Treated Patient Volume Forecast
3.1.6 The U.S. Doptelet CIT Treated Patient Volume Forecast
3.1.7 The U.S. CLD Patient Volume Forecast
3.1.8 The U.S. CLD Patient Volume with Severe Thrombocytopenia Forecast
3.1.9 The U.S. CLD Treated Patient Volume with Severe Thrombocytopenia Forecast
3.2 ROW (Rest of World)
3.2.1 ROW ITP Total Patient Volume Forecast
3.2.2 ROW ITP Treated Patient Volume Forecast
3.2.3 ROW CIT Total Patient Volume Forecast
3.2.4 ROW CIT Treated Patient Volume Forecast
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising HealthCare Expenditure
4.1.2 Growing Female Population
4.1.3 Rising Prevalence of Arthritis
4.1.4 Increasing Incidences of Hepatitis C
4.1.5 New Cases of Diagnosed Cancer
4.2 Key Trends & Development
4.2.1 Novel Drug Development for Thrombocytopenia
4.2.2 Increasing Number of Awareness Programs about Thrombocytopenia
4.2.3 Increase in Pharmaceutical R&D Expenditures
4.2.4 Increasing Preference for Biosimilars
4.3.1 Lethargic Drug Approval Process
4.3.2 Side Effects Associated With Available Thrombocytopenia Drugs
4.3.3 Availability of Alternative Treatment Options
Causes of Thrombocytopenia
The U.S. Diagnosed Arthritis Population (2000-2020)
Hepatitis C Population in Major Regions (2018)
Global New Cases of Diagnosed Cancer (2018)
Key Players - Available Drugs for Chronic Thrombocytopenia
Key Players - Revenue Comparison (2018)
Key Players - Market Cap Comparison (2019)
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Pharmaceutical
PharmaceuticalChinese Markets for Mental Illness Drugs
PharmaceuticalChinese Markets for Anti-Dermatomycosis Skin Drugs
PharmaceuticalChinese Markets for Incretion Drugs
PharmaceuticalChinese Markets for Hypertension Drugs
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017